

Characteristics of drug resistant HBV in an international HIV-HBV-infected individuals on extended lamivudine

Aids

20, 863-870

DOI: 10.1097/01.aids.0000218550.85081.59

Citation Report

#	ARTICLE	IF	CITATIONS
1	Management of chronic hepatitis B in challenging patient populations. Liver International, 2006, 26, 38-46.	3.9	9
2	Impact of Highly Active Antiretroviral Therapy (HAART) on the Natural History of Hepatitis B Virus (HBV) and HIV Coinfection: Relationship between Prolonged Efficacy of HAART and HBV Surface and Early Antigen Seroconversion. Clinical Infectious Diseases, 2007, 45, 624-632.	5.8	76
3	Hepatitis B Virus Genotypes and Lamivudine Resistance Mutations in HIV/Hepatitis B Virus-Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 557-561.	2.1	53
4	Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. Aids, 2007, 21, 1701-1710.	2.2	36
5	The management of HIV and hepatitis B coinfection. Current Opinion in Infectious Diseases, 2007, 20, 16-21.	3.1	15
6	Hepatitis B reverse seroconversion in HIV-positive patients: case series and review of the literature. Aids, 2007, 21, 771-774.	2.2	31
7	Selection of Hepatitis B Virus (HBV) Vaccine Escape Mutants in HBV-Infected and HBV/HIV-Coinfected Patients Failing Antiretroviral Drugs With Anti-HBV Activity. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 279-282.	2.1	54
8	Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infectious Diseases, The, 2007, 7, 402-409.	9.1	285
9	The L80I Substitution in the Reverse Transcriptase Domain of the Hepatitis B Virus Polymerase Is Associated with Lamivudine Resistance and Enhanced Viral Replication In Vitro. Antimicrobial Agents and Chemotherapy, 2007, 51, 2285-2292.	3.2	92
10	Prophylaxis and treatment of hepatitis B in immunocompromised patients. Digestive and Liver Disease, 2007, 39, 397-408.	0.9	197
12	Ten years of highly active antiretroviral therapy for HIV infection. Medical Journal of Australia, 2007, 186, 146-151.	1.7	85
13	Management of hepatitis B: Summary of a clinical research workshop. Hepatology, 2007, 45, 1056-1075.	7.3	568
14	Cathodic adsorptive stripping voltammetric studies on lamivudine: An antiretroviral drug. Journal of Colloid and Interface Science, 2007, 313, 254-260.	9.4	21
15	Viral hepatitis in patients with HIV infection. Current Hepatitis Reports, 2007, 6, 103-113.	0.3	0
16	Management of hepatitis B virus co-infection on and off antiretroviral therapy. Current HIV/AIDS Reports, 2008, 5, 86-93.	3.1	9
17	Evaluation and treatment of the patient coinfecting with hepatitis B and HIV. Current HIV/AIDS Reports, 2008, 5, 103-11.	3.1	3
18	Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance. Hepatology, 2008, 48, 741-749.	7.3	24
19	A randomized trial of combination hepatitis B therapy in HIV/HBV coinfecting antiretroviral naïve individuals in Thailand. Hepatology, 2008, 48, 1062-1069.	7.3	121

#	ARTICLE	IF	CITATIONS
20	Current treatment of HIV/hepatitis B virus coinfection. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 699-706.	2.8	24
21	Treatment of chronic hepatitis B and the implications of viral resistance to therapy. Expert Review of Anti-Infective Therapy, 2008, 6, 191-199.	4.4	7
23	Effect of the HIV epidemic on liver cancer in Africa. Lancet, The, 2008, 371, 1504.	13.7	7
24	HIV and hepatitis B co-infection in Africa. Lancet Infectious Diseases, The, 2008, 8, 210-211.	9.1	9
25	A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update. Clinical Gastroenterology and Hepatology, 2008, 6, 1315-1341.	4.4	450
26	Alanine aminotransferase levels are not significantly elevated in patients with HIV/HBV co-infection and lamivudine resistance. International Journal of STD and AIDS, 2008, 19, 780-781.	1.1	2
27	Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. Aids, 2008, 22, 1399-1410.	2.2	149
28	Hepatitis B virus escape mutants induced by antiviral therapy. Journal of Antimicrobial Chemotherapy, 2008, 61, 766-768.	3.0	115
29	Frequent Occurrence of Chronic Hepatitis B Virus Infection among West African HIV Type-1-Infected Children. Clinical Infectious Diseases, 2008, 46, 361-366.	5.8	44
30	Hepatitis B Virus and HIV Coinfection in Low-Income Countries: Unmet Needs. Clinical Infectious Diseases, 2008, 46, 367-369.	5.8	25
31	The implications of antiviral drugs with activity against hepatitis B virus and HIV. Current Opinion in Internal Medicine, 2008, 7, 57-64.	1.5	3
32	Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. Therapeutics and Clinical Risk Management, 2009, 5, 789.	2.0	12
33	Pharmacotherapy of Chronic Hepatitis B in Adults: Focus on Tenofovir Disoproxil Fumarate. Clinical Medicine Therapeutics, 2009, 1, CMT.S1161.	0.1	0
34	Use of Massively Parallel Ultradeep Pyrosequencing To Characterize the Genetic Diversity of Hepatitis B Virus in Drug-Resistant and Drug-Naïve Patients and To Detect Minor Variants in Reverse Transcriptase and Hepatitis B S Antigen. Journal of Virology, 2009, 83, 1718-1726.	3.4	143
35	A sensitive direct sequencing assay based on nested PCR for the detection of HBV polymerase and surface glycoprotein mutations. Journal of Virological Methods, 2009, 159, 53-57.	2.1	15
37	Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfecting individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy. Hepatology, 2009, 49, 1113-1121.	7.3	22
38	Hepatitis B and human immunodeficiency virus coinfection. Hepatology, 2009, 49, S138-S145.	7.3	263
39	Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B. Journal of Medical Virology, 2009, 81, 1151-1156.	5.0	16

#	ARTICLE	IF	CITATIONS
40	Prolonged use of tenofovir in HIV/hepatitis B virus (HBV) coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations. HIV Medicine, 2009, 10, 229-235.	2.2	34
41	Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV coinfected cohort. HIV Medicine, 2009, 10, 269-273.	2.2	17
42	The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. Journal of Hepatology, 2009, 50, 461-470.	3.7	39
44	Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. Aids, 2009, 23, 1707-1715.	2.2	50
45	Future directions in the treatment of HIV-HBV coinfection. HIV Therapy, 2009, 3, 405-415.	0.6	7
46	Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. Aids, 2010, 24, 857-865.	2.2	59
47	Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naïve HIV-HBV coinfection in Thailand. Antiviral Therapy, 2010, 15, 917-922.	1.0	29
48	Drug-resistant and immune-escape HBV mutants in HIV-infected hosts. Antiviral Therapy, 2010, 15, 493-497.	1.0	21
49	Differential inhibition of lamivudine-resistant hepatitis B virus by allele-specific RNAi. Journal of Virological Methods, 2010, 168, 6-12.	2.1	3
50	Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health, 2010, 10, 105.	2.9	27
51	Viral hepatitis and HIV co-infection. Antiviral Research, 2010, 85, 303-315.	4.1	177
52	High frequency of lamivudine resistance mutations in Brazilian patients coinfected with HIV and hepatitis B. Journal of Medical Virology, 2010, 82, 1481-1488.	5.0	15
53	High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy. HIV Medicine, 2010, 11, 85-89.	2.2	31
54	British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Medicine, 2010, 11, 1-30.	2.2	73
55	Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. Journal of Viral Hepatitis, 2010, 17, 807-815.	2.0	85
56	Hepatitis B genotype G and high frequency of lamivudine-resistance mutations among human immunodeficiencyvirus/hepatitis B virus co-infected patients in Brazil. Memórias Do Instituto Oswaldo Cruz, 2010, 105, 770-778.	1.6	16
57	Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy. Antiviral Therapy, 2010, 15, 487-491.	1.0	6
58	Managing HBV in patients with impaired immunity. Gut, 2010, 59, 1430-1445.	12.1	63

#	ARTICLE	IF	CITATIONS
59	New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients. Journal of Antimicrobial Chemotherapy, 2010, 65, 379-382.	3.0	10
60	Hepatitis B Virus Drug Resistance in HIV-Infected Patients Taking Lamivudine-Containing Antiretroviral Therapy. AIDS Patient Care and STDs, 2010, 24, 205-209.	2.5	13
61	Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study. Journal of Hepatology, 2010, 53, 1006-1012.	3.7	46
63	HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain. Antiviral Therapy, 2011, 16, 585-589.	1.0	18
64	Lamivudine-Resistant HBV Infection in HIV-Positive Patients Receiving Antiretroviral Therapy in a Public Routine Clinic in Cameroon. Antiviral Therapy, 2012, 17, 321-326.	1.0	31
65	HBV lamivudine resistance among hepatitis B and HIV coinfecting patients starting lamivudine, stavudine and nevirapine in Kenya. Journal of Viral Hepatitis, 2011, 18, e447-e452.	2.0	24
66	Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B. Journal of Medical Virology, 2011, 83, 1905-1908.	5.0	3
67	Dimension reduced kernel estimation for distribution function with incomplete data. Journal of Statistical Planning and Inference, 2011, 141, 3084-3093.	0.6	8
68	Detection of Hepatitis B Virus Variants in HBV Monoinfected and HBV/HIV Coinfected Iranian Patients Under Lamivudine Treatment. Current HIV Research, 2011, 9, 263-269.	0.5	6
70	Detection of hepatitis B virus genotype A3 and primary drug resistance mutations in African immigrants with chronic hepatitis B in Spain. Journal of Antimicrobial Chemotherapy, 2011, 66, 641-644.	3.0	15
71	Republished paper: Managing HBV in patients with impaired immunity. Postgraduate Medical Journal, 2011, 87, 223-238.	1.8	3
72	Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients. ISRN Gastroenterology, 2011, 2011, 1-6.	1.5	9
73	Liver disease, HIV and aging. Sexual Health, 2011, 8, 512.	0.9	16
74	Immunological and virological responses to combined antiretroviral therapy in HIV/hepatitis B virus-coinfected patients from a multicenter cohort. Aids, 2012, 26, 1755-1763.	2.2	40
75	Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection. Journal of Clinical Virology, 2012, 54, 194-196.	3.1	10
77	Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi. Journal of Medical Virology, 2012, 84, 1553-1557.	5.0	13
78	Management of Chronic Hepatitis B: Canadian Association for the Study of the Liver Consensus Guidelines. Canadian Journal of Gastroenterology & Hepatology, 2012, 26, 917-938.	1.7	60
79	Clinical and virological characteristics of hepatitis B or C virus co-infection with HIV in Indonesian patients. Journal of Medical Virology, 2012, 84, 857-865.	5.0	31

#	ARTICLE	IF	CITATIONS
80	8.0, Antiretroviral therapy in specific populations. HIV Medicine, 2012, 13, 57-81.	2.2	1
81	Comparative analysis of hepatitis B virus genotype a molecular evolution in patients infected with HBV and in patients co-infected with HBV and HIV. Journal of Medical Virology, 2012, 84, 562-569.	5.0	8
83	Hepatitis B in HIV-Infected Patients. Clinics in Liver Disease, 2013, 17, 489-501.	2.1	24
84	Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients. Journal of Clinical Virology, 2013, 57, 103-108.	3.1	35
85	High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients. Hepatology, 2013, 58, 912-922.	7.3	37
86	HIV/HBV coinfection in children and antiviral therapy. Expert Review of Anti-Infective Therapy, 2013, 11, 251-263.	4.4	16
87	Prevalence and Clinical and Immunovirological Profile of Human Immunodeficiency Virus-Hepatitis B Coinfection among Children in an Antiretroviral Therapy Programme in Benue State, Nigeria. ISRN Pediatrics, 2013, 2013, 1-7.	1.2	32
88	Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. Aids, 2013, 27, 191-201.	2.2	80
89	Hepatitis B virus in HIV-infected patients in north-eastern South Africa: Prevalence, exposure, protection and response to HAART. South African Medical Journal, 2013, 103, 330.	0.6	16
90	Prevalence, Clinical and Virologic Outcomes of Hepatitis B Virus Co-Infection in HIV-1 Positive Kenyan Women on Antiretroviral Therapy. PLoS ONE, 2013, 8, e59346.	2.5	28
91	Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: A review. World Journal of Gastroenterology, 2014, 20, 14598.	3.3	78
92	Management and treatment of chronic hepatitis B in HIV-positive patients. Annals of Medicine, 2014, 46, 290-296.	3.8	11
93	High seroprevalence of hepatitis B virus and hepatitis C virus among human immunodeficiency virus carriers in blood donors of Burkina Faso: a need for their screening before <sc>HAART</sc> therapy. Journal of Viral Hepatitis, 2014, 21, e52-3.	2.0	4
94	Hepatitis B Virus Sub-genotype A1 Infection Is Characterized by High Replication Levels and Rapid Emergence of Drug Resistance in HIV-Positive Adults Receiving First-line Antiretroviral Therapy in Malawi. Clinical Infectious Diseases, 2014, 59, 1618-1626.	5.8	29
95	Epidemiology and impact of HIV coinfection with Hepatitis B and Hepatitis C viruses in Sub-Saharan Africa. Journal of Clinical Virology, 2014, 61, 20-33.	3.1	138
96	Factors Associated With Delayed Hepatitis B Viral Suppression on Tenofovir Among Patients Coinfected With HBV-HIV in the CNICS Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 96-101.	2.1	23
97	High Incidence of Lamivudine-Resistance-Associated Vaccine-Escape HBV Mutants among HIV-Coinfected Patients on Prolonged Antiretroviral Therapy. Antiviral Therapy, 2015, 20, 545-554.	1.0	14
98	Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort. Aids, 2015, 29, 1173-1182.	2.2	18

#	ARTICLE	IF	CITATIONS
99	Genetic Diversity of the Hepatitis B Virus Strains in Cuba: Absence of West-African Genotypes despite the Transatlantic Slave Trade. PLoS ONE, 2015, 10, e0125052.	2.5	9
100	Towards the elimination and eradication of hepatitis B. Journal of Virus Eradication, 2015, 1, 4-12.	0.5	7
101	Anti-Retroviral Drug Hepatotoxicity and Risk Factors in HIV Patients with or Without Hepatitis B and C: A Review. Journal of Infectious Disease and Therapy, 2015, 03, .	0.1	3
102	Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana. Clinical Infectious Diseases, 2015, 61, 883-891.	5.8	53
103	Advances in treating drug-resistant hepatitis B virus in HIV-infected patients. Expert Opinion on Pharmacotherapy, 2015, 16, 179-186.	1.8	7
104	A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. Clinical Gastroenterology and Hepatology, 2015, 13, 2071-2087.e16.	4.4	90
105	Epidemiology of HBV infection in a cohort of Ugandan HIV-infected patients and rate and pattern of lamivudine-resistant HBV infection in patients receiving antiretroviral therapy. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2015, 109, 723-729.	1.8	9
106	Hepatitis B Virus. , 2016, , 713-770.		2
107	Chronic Hepatitis B, C, and D. Microbiology Spectrum, 2016, 4, .	3.0	2
108	Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor. Clinical Microbiology and Infection, 2016, 22, 946.e1-946.e8.	6.0	25
109	HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia. Antiviral Therapy, 2016, 22, 97-111.	1.0	12
110	Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 39-45.	2.1	22
111	Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal. BMC Infectious Diseases, 2017, 17, 566.	2.9	9
112	Evolution of hepatitis B serological markers in HIV coinfecting patients: a case study. Revista De Saude Publica, 2017, 51, 24.	1.7	11
113	Molecular Virology and Life Cycle. , 2018, , 1-23.		1
114	Lamivudine Plus Tenofovir versus Lamivudine Plus Adefovir for the Treatment of Hepatitis B Virus in HIV-Coinfected Patients, Starting Antiretroviral Therapy. Indian Journal of Medical Microbiology, 2018, 36, 217-223.	0.8	9
115	HIV and the Liver. , 2018, , 536-555.e7.		1
116	High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China. Intervirology, 2018, 61, 123-132.	2.8	7

#	ARTICLE	IF	CITATIONS
117	Uptake of hepatitis B-HIV co-infection screening and management in a resource limited setting. <i>Hepatology, Medicine and Policy</i> , 2018, 3, 3.	1.7	1
118	Antiretroviral Effects on HBV/HIV Co-infection and the Natural History of Liver Disease. <i>Clinics in Liver Disease</i> , 2019, 23, 473-486.	2.1	2
119	Management of Virologic Failure and HIV Drug Resistance. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 707-742.	5.1	40
120	HBV Infection in HIV-Driven Immune Suppression. <i>Viruses</i> , 2019, 11, 1077.	3.3	26
121	Hepatitis B virus coinfection is associated with high early mortality in HIV-infected Tanzanians on antiretroviral therapy. <i>Aids</i> , 2019, 33, 465-473.	2.2	14
122	Hepatitis B Infection in People Living With Human Immunodeficiency Virus: A Global Challenge Needing More Research. <i>Clinical Infectious Diseases</i> , 2020, 71, 2807-2809.	5.8	1
123	Decreased All-Cause and Liver-Related Mortality Risk in HIV/Hepatitis B Virus Coinfection Coinciding With the Introduction of Tenofovir-Containing Combination Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa226.	0.9	16
124	Chronic Hepatitis B and HIV Coinfection: a Continuing Challenge in the Era of Antiretroviral Therapy. <i>Current Hepatology Reports</i> , 2020, 19, 345-353.	0.9	9
125	Challenges for hepatitis B virus cure in resource-limited settings in sub-Saharan Africa. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 185-192.	3.8	11
126	Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection. <i>Current HIV/AIDS Reports</i> , 2020, 17, 405-414.	3.1	22
127	Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review. <i>Viruses</i> , 2021, 13, 1341.	3.3	11
128	The Hepatitis B Virus and Antiviral Drug Resistance: Causes, Patterns, and Mechanisms. , 2009, , 519-530.		1
129	Hepatitis B Virus and Hepatitis Delta Virus. , 2010, , 2059-2086.		5
130	Hepatitis B Virus and Hepatitis Delta Virus. , 2015, , 1815-1839.e7.		17
131	Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection. <i>Liver International</i> , 2019, 39, 1408-1417.	3.9	13
132	A Multicentre Molecular Analysis of Hepatitis B and Blood-Borne Virus Coinfections in Viet Nam. <i>PLoS ONE</i> , 2012, 7, e39027.	2.5	56
133	Long-Term Hepatitis B Virus (HBV) Response to Lamivudine-Containing Highly Active Antiretroviral Therapy in HIV-HBV Co-Infected Patients in Thailand. <i>PLoS ONE</i> , 2012, 7, e42184.	2.5	10
134	Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China. <i>PLoS ONE</i> , 2015, 10, e0134539.	2.5	18

#	ARTICLE	IF	CITATIONS
135	Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization?. Bulletin of the World Health Organization, 2010, 88, 66-73.	3.3	330
136	MANAGEMENT OF HBV INFECTION DURING IMMUNOSUPPRESSIVE TREATMENT. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009025.	1.3	9
137	Insights into human immunodeficiency virus-hepatitis B virus co-infection in India. World Journal of Virology, 2015, 4, 255.	2.9	3
138	Treatment of Hepatitis B in HIV-Infected Persons. , 2012, , 141-149.		0
139	Chronic Hepatitis B, C, and D. , 0, , 69-95.		0
140	The Hepatitis B Virus and Antiviral Drug Resistance: Causes, Patterns and Mechanisms. , 2017, , 565-577.		1
141	Optimal Control Dynamics: Multi-therapies with Dual Immune Response for Treatment of Dual Delayed HIV-HBV Infections. International Journal of Mathematical Sciences and Computing, 2020, 6, 18-60.	0.7	0
143	A Review of the 2010 WHO Adult Antiretroviral Therapy Guidelines: Implications and Realities of These Changes for Zambia. Medical Journal of Zambia, 2010, 37, 118-124.	0.1	2
144	Towards the elimination and eradication of hepatitis B. Journal of Virus Eradication, 2015, 1, 4-12.	0.5	5
145	Hepatitis B Virus-HIV Coinfection: Forgotten but Not Gone. Gastroenterology and Hepatology, 2014, 10, 780-8.	0.1	3
146	Persistent Hepatitis B Viraemia with Polymerase Mutations among HIV/HBV Co-Infected Patients on HBV-Active ART in KwaZulu-Natal, South Africa. Viruses, 2022, 14, 788.	3.3	3
147	Hepatitis B Virus Genotypes and Antiviral Resistance Mutations in Romanian HIV-HBV Co-Infected Patients. Medicina (Lithuania), 2022, 58, 531.	2.0	2
149	Diagnosis, Diagnostic Tests and Monitoring of Hepatitis B Virus in Monoinfected and HIV-Coinfected Patients. Antiviral Therapy, 2007, 12, 25-31.	1.0	14
150	Major Causes of Antiviral drug Resistance and Implications for Treatment of Hepatitis B virus Mono-infection and Coinfection with HIV. Antiviral Therapy, 2007, 12, 15-23.	1.0	71
151	Special Considerations and Treatment of Patients with HBV-HIV Coinfection. Antiviral Therapy, 2007, 12, 43-51.	1.0	6
152	Evidence of Long-Term Suppression of Hepatitis B virus DNA by Tenofovir as Rescue Treatment in Patients Coinfected by HIV. Antiviral Therapy, 2008, 13, 341-348.	1.0	13
153	The pathogenesis of liver disease in the setting of HIV–hepatitis B virus coinfection. Antiviral Therapy, 2009, 14, 155-164.	1.0	18
154	Improvements in Parameters of End-Stage Liver Disease in Patients with HIV/HBV-related Cirrhosis Treated with Tenofovir. Antiviral Therapy, 2007, 12, 119-122.	1.0	31

#	ARTICLE	IF	CITATIONS
155	Virological Responses to Tenofovir Alafenamide-Containing Antiretroviral Therapy in People Living with HIV Who Had Lamivudine-Resistant and Lamivudine-Susceptible Hepatitis B Virus Coinfection. International Journal of Antimicrobial Agents, 2022, , 106682.	2.5	2
156	HIV: hepatic manifestations of HIV and antiretroviral therapy. , 2023, , 525-555.		0
157	A review on the epidemiology of HBV and HIV co-infection. CHRISMED Journal of Health and Research, 2023, 10, 1.	0.0	0
158	High frequency of Lamivudine and Telbivudine resistance mutations in hepatitis B virus isolates from human immunodeficiency virus co-infected patients on highly active antiretroviral therapy in Bucaramanga, Colombia. Frontiers in Microbiology, 0, 14, .	3.5	1
159	Comparison of Antiretroviral Therapies in Pregnant Women Living With Human Immunodeficiency Virus and Hepatitis B Virus. Obstetrics and Gynecology, 2023, 142, 613-624.	2.4	0